CARM · As filed with the SEC
Carisma Therapeutics income statement, by fiscal year
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|
| Collaboration revenues | 19,632 | 14,919 | 9,834 |
| Operating expenses: | |||
| Research and development | 59,673 | 74,125 | 56,618 |
| General and administrative | 22,138 | 29,525 | 9,378 |
| Total operating expenses | 81,811 | 103,650 | 65,996 |
| Operating loss | (62,179) | (88,731) | (56,162) |
| Change in fair value of derivative liability | 0 | (84) | (1,919) |
| Interest income, net | 1,702 | 1,936 | (3,145) |
| Net loss | (60,477) | (86,879) | (61,226) |
| Share information: | |||
| Net loss per share of common stock, basic (in USD per share) | (1.46) | (2.59) | (28.77) |
| Net loss per share of common stock, diluted (in USD per share) | (1.46) | (2.59) | (28.77) |
| Weighted-average shares of common stock outstanding, basic (in shares) | 41,456,210 | 33,524,197 | 2,128,069 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 41,456,210 | 33,524,197 | 2,128,069 |
| Comprehensive loss | |||
| Net loss | (60,477) | (86,879) | (61,226) |
| Unrealized gain on marketable securities | 0 | 440 | (41) |
| Less: reclassification to net loss of previous unrealized gain on marketable securities | 0 | (399) | 0 |
| Comprehensive loss | (60,477) | (86,838) | (61,267) |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.